FindTrial
Sign In

Role and Mechanism of CPT1C in Mediating Cancer-Associated Fibroblast Senescence via Lipid Metabolic Reprogramming to Promote Gastric Cancer Malignant Progression and Immune Evasion

Role and Mechanism of CPT1C in Mediating Cancer-Associated Fibroblast Senescence via Lipid Metabolic Reprogramming to Promote Gastric Cancer Malignant Progression and Immune Evasion

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600122118
Enrollment
Unknown
Registered
2026-04-09
Start date
2026-04-09
Completion date
Unknown
Last updated
2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric cancer

Interventions

Gastric Malignant Tumor Observation Group:None

Sponsors

Ningbo Medical Centre Lihuili Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with gastric adenocarcinoma confirmed by preoperative endoscopic biopsy pathology, or with a high clinical suspicion of gastric adenocarcinoma, who have an indication for surgical resection.

Exclusion criteria

Exclusion criteria: 1.Unable to provide sufficient tumor tissue and paired adjacent normal tissue specimens. 2.Postoperative pathology: not gastric adenocarcinoma — does not meet the study's histopathological criteria. 3.No signed informed consent / declined participation in this study. 4.Received other anticancer treatments (e.g., chemotherapy, radiotherapy) within 3 months prior to study enrollment.

Design outcomes

Primary

MeasureTime frame
mRNA level and protein level;The staining ratio of immunohistochemical staining;—

Countries

China

Contacts

Public ContactFangqian Chen

Ningbo Medical Centre Lihuili Hospital

lhlchenfangqian@nbu.edu.cn+86 571 8701 8107

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 17, 2026